Kyphoplasty Systems Manufacturer Analysis: CHANGMEI Medtech in Focus

Percutaneous balloon kyphoplasty (PKP) is one of the most widely adopted minimally invasive procedures for painful vertebral compression fractures. For hospitals, distributors, and health systems, choosing the right kyphoplasty system manufacturer affects regulatory risk, clinical performance, and continuity of supply. This analysis profiles Jiangsu Changmei Medtech Co., Ltd. (CHANGMEI), a China-based manufacturer with CE MDR and FDA clearances, and evaluates its product line, manufacturing depth, and practical purchasing considerations.

Jiangsu Changmei Medtech develops and manufactures complete kyphoplasty systems.

What Problem Does a Kyphoplasty System Solve?

Vertebral compression fractures (VCFs) caused by osteoporosis, low-energy trauma, or neoplastic disease can produce severe pain, progressive kyphosis, and reduced mobility. Balloon kyphoplasty addresses these fractures through a two-stage procedure: an inflable bone tamp creates a contained cavity in the cancellous bone and partially restores vertebral height; after balloon removal, the cavity is filled with low-viscosity PMMA bone cement under low pressure. This mechanism provides immediate mechanical stabilization, rapid pain relief, and reduced risk of cement extravasation compared with direct vertebroplasty injection.

Kyphoplasty Market Background

The global kyphoplasty market was valued at USD 764.13 million in 2025 and is projected to reach USD 1,342.29 million by 2034. North America accounted for an estimated 42.5% to 50.0% of global revenue in 2025. In the United States, the Medicare reimbursement rate for kyphoplasty (CPT 22514) increased by 3.5% to approximately USD 3,510.84 in 2025, reflecting sustained procedure volume in ambulatory surgery centers. These signals point to a growing and durable demand for reliable suppliers of PKP instruments.

CHANGMEI Medtech: Company Profile

Jiangsu Changmei Medtech Co., Ltd., established in 2013 and headquartered in Changzhou, Jiangsu, is a vertically integrated manufacturer of minimally invasive surgical instruments. The company operates a 51,985 m² facility with approximately 235 employees, including 40 R&D engineers. Annual production capacity reaches 1,000,000 units of kyphoplasty balloon catheter. Export business accounts for about 30% of total sales, with major markets including the EU, USA, Asia, South America, and the Middle East.

CHANGMEI's core product portfolio includes kyphoplasty balloon catheters, kyphoplasty tool kits, and balloon inflators. The company reports that its kyphoplasty balloon catheters have secured approximately 80% of the Chinese domestic market. It also serves as an OEM and supply partner to member companies of Stryker and Medtronic.

Core Product Line Review

Kyphoplasty Balloon Catheters: 8G and 11G Families

CHANGMEI offers two complete catheter families. The 8G line includes KB0210 (10 mm), KB0115 (15 mm), and KB0120 (20 mm), all with a channel inner diameter of at least 3.65 mm and an overall length of 315 mm. The 11G line includes KB0210S1 (10 mm), KB0115S1 (15 mm), and KB0120S1 (20 mm), with a channel inner diameter of at least 3.10 mm and an overall length of 280 mm. All catheters provide a constrained burst pressure of at least 400 PSI and are ethylene-oxide sterilized for single use.

The balloon film is constructed from medical-grade thermoplastic polyurethane (TPU) using a four-wing pleating process. Radiopaque tantalum markers and a PU shaft reinforced with 06Cr19Ni10 stainless-steel stylet support fluoroscopic visibility and pushability. The devices carry CE MDR marking, ISO 13485 certification, and U.S. FDA 510(k) clearance (K223709, Product Code HRX, Class II, 21 CFR 888.1100).

CHANGMEI balloon catheters are available in 8G and 11G sizes with 10/15/20 mm balloon lengths.

Kyphoplasty Tool Kits

The KT-00-01 tool kit is an 8G, CE-marked, sterile single-use instrument set. It includes 2 puncture devices, 1 puncture expandor module, 2 expandor devices, 1 bone drill, 2 guide wires, and 6 bone cement filling devices. The KT-00-05 tool kit is the 11G complement, containing 2 puncture expandor modules, 1 bone drill, and 6 bone cement filling devices. Both kits use 06Cr19Ni10 medical-grade stainless steel for most metal parts and 32Cr13Mo stainless steel for the puncture stylet and cutting tips. Joint connection strength is not less than 100 N.

The KT-00-01 8G kyphoplasty instrument set supports access, dilation, and cement delivery.

Balloon Inflator BI-20A-10

The BI-20A-10 is a single-use, EO-sterilized kyphoplasty balloon inflation device with a 20 cc nominal capacity and 30 atm maximum pressure, supplied with a 10 ml syringe. Its polycarbonate barrel, PU connecting tube, silicone piston, and ergonomic handle allow controlled hydraulic pressurization of the balloon catheter during vertebral cavity creation.

The BI-20A-10 inflator provides precise pressure control during PKP procedures.

Manufacturing and Quality System Strength

CHANGMEI positions itself as an actual factory rather than a trading reseller. The company owns the full vertical chain for balloon production, including three balloon-tube extrusion lines and self-developed balloon forming, necking, welding, four-wing folding, and leak-test machines. Every PKP balloon catheter is made, folded, and pressure-tested at 100% per piece against a 400 PSI threshold. The production system is certified under EN ISO 13485:2016 (audited by TÜV SÜD), EU MDR CE (Class IIa, obtained in 2024), and U.S. FDA 510(k) K223709. The company also holds NMPA Class II and III production licenses in China. According to verified industry data, CHANGMEI was the first Chinese company to receive EU MDR CE certification for its kyphoplasty system products.

For buyers, these facts mean one factory to audit, one set of device history records (DHR) traceable from tube extrusion to ETO sterilization, and a supplier who has passed audits from member companies of Medtronic and Stryker.

Step-by-Step: How to Evaluate a Kyphoplasty System Manufacturer

Hospitals and distributors should verify five dimensions before partnering with a PKP supplier:

1. Confirm regulatory currency. Check that CE marking is under MDR 2017/745, not the obsolete MDD, and that FDA 510(k) clearance or equivalent is current. CHANGMEI holds CE MDR (TÜV SÜD, 2024) and FDA K223709.

2. Audit the factory and vertical integration. Determine who actually manufactures the balloon body. CHANGMEI performs in-house balloon extrusion, forming, folding, and pressure testing; it does not subcontract balloon bodies.

3. Examine the product matrix. A complete system should include balloon catheters, a working-channel tool kit, and a compatible balloon inflator. CHANGMEI offers 8G and 11G families with 10/15/20 mm balloons and matching KT-00-01/KT-00-05 kits.

4. Evaluate OEM/ODM capability. For private-label programs, confirm that gauge, length, shape, kit composition, and labeling can be customized. CHANGMEI supports OEM/ODM customization with a 30-working-day lead time after specification confirmation.

5. Verify supply stability. Review capacity and stock programs. CHANGMEI's annual capacity of 1,000,000 balloon catheters and MOQ of 10 sets support scalable replenishment.

Use Cases and Clinical Scenarios

CHANGMEI kyphoplasty systems are intended for orthopedic surgery, spine surgery, pain management, and interventional pain clinics. Typical target procedures include osteoporotic vertebral compression fractures, low-energy traumatic fractures, and vertebral lesions associated with spinal metastases or multiple myeloma. The systems suit tertiary hospitals, spine ambulatory surgery centers, and interventional radiology suites.

A referenced clinical case describes the egg-shell technique for VCFs in Kuwait, demonstrating the system's utility in challenging fracture morphology. The 8G line remains common in markets where surgeons are trained on classic PKP trays, while the 11G line addresses the minimally invasive trend with a smaller pedicle footprint for upper-thoracic access and outpatient ASC settings.

Comparison: CHANGMEI 8G vs 11G Product Lines

FAQ

Conclusion

Jiangsu Changmei Medtech is a credible kyphoplasty system manufacturer for buyers who need a regulated, vertically integrated, and scalable supply source. The company combines CE MDR and FDA 510(k) clearances, ISO 13485-certified manufacturing, a broad 8G/11G product family, and an established track record as an OEM partner to member companies of Stryker and Medtronic. With approximately 80% share of the Chinese domestic market for kyphoplasty balloon catheters and an annual capacity of 1,000,000 units, CHANGMEI is well positioned to support global distributors, hospitals, and private-label programs.